X0306 4 2015-02-27 0 0001623613 Mylan N.V. MYL 0001113186 LEECH DOUGLAS J ALBANY GATE, DARKES LANE POTTERS BAR, HERTFORDSHIRE X0 EN6 1AG UNITED KINGDOM 1 0 0 0 Ordinary Shares 2015-02-27 4 A 0 31380 A 31380 D Non-Employee Director Stock Option - Right to Buy 45.72 2015-02-27 4 A 0 2974 A 2024-04-11 Ordinary Shares 2974 2974 D On February 27, 2015 (the "Closing Date"), Mylan N.V. completed the transaction (the "Transaction") by which it acquired Mylan Inc. and Abbott Laboratories' ("Abbott") non-U.S. developed markets specialty and branded generics business (the "Business"). Pursuant to the terms of the Amended and Restated Business Transfer Agreement and Plan of Merger, dated as of November 4, 2014, by and among Mylan Inc., New Moon B.V. (which has been renamed Mylan N.V. and is referred to herein as "Mylan"), Moon of PA Inc. ("Merger Sub"), and Abbott, on the Closing Date, Mylan acquired the Business and Merger Sub merged with and into Mylan Inc., with Mylan Inc. surviving as a wholly owned indirect subsidiary of Mylan and each share of Mylan Inc. common stock issued and outstanding was cancelled and automatically converted into and became the right to receive one Mylan ordinary share (the "Merger"). (Continued in Footnote 2) In connection with the Transaction, Mylan Inc. and the Business have been reorganized under Mylan, a new public company organized in the Netherlands. Represents ordinary shares of Mylan acquired in connection with the Transaction on a one-for-one basis in exchange for shares of Mylan Inc. common stock. On the effective date of the Merger, the closing price of MYL was $57.33 per share. Received in exchange for, and having substantially the same terms as, stock options of Mylan Inc. common stock in connection with the Transaction. These options will vest in full on April 11, 2015. /s/ Bradley L. Wideman, by power of attorney 2015-02-27